ARTICLE
Changes to Public Procurement in The United Kingdom Post Brexit
March 10, 2021
Read time: 1 min

ARTICLE
March 10, 2021
Read time: 1 min

ARTICLE
March 3, 2021
Read time: 2 min
Dr Nils Christian Wighardt and Jonathan Storz explain the reasons for involving young family members in family enterprises at an early stage. To protect young family members as well as the family enterprise, the involvement of the juniors should be accompanied by specific regulations in the shareholder agreement. Although this does not guarantee a successful business succession, in many cases it leads to an emotional bond between the successor and the company. The involvement of young family members is also attractive from a tax point of view.

ARTICLE
March, 2021
Read time: 1 min

ARTICLE / CLIENT ALERT
March 9, 2021
Read time: 5 min
On March 5, 2021, the Securities and Exchange Commission charged AT&T with violating Regulation FD (“Reg FD”) for selectively disclosing material nonpublic information (“MNPI”) to research analysts.[1] The SEC has brought only a handful of Reg FD cases since its enactment in 2000, and this case may have significant implications for investment professionals.
Regulation FD prohibits issuers, or persons acting on their behalf, from disclosing MNPI to certain third parties without disclosing that same information to the general public. Reg FD was enacted, primarily, to prevent public companies from selectively providing nonpublic earnings information to securities analysts and certain shareholders. The goal of Reg FD was to level the playing field between individual and institutional investors following publicized reports of institutional investors profiting in advance of corporate earnings announcements. Final Rule: Selective Disclosure and Insider Trading, Exchange Act Rel. No. 43154, 65 Fed. Reg. 51, 721 (Aug. 15, 2000) (https://www.sec.gov/rules/final/33-7881.htm).
According to the SEC’s complaint filed against AT&T last week, AT&T had experienced an unanticipated decline in its first quarter 2016 smartphone sales. To avoid falling short of Wall Street’s consensus revenue estimate, the SEC alleged that AT&T investor relations executives made private, one-on-one phone calls to equity analysts at approximately 20 different sell-side firms during which they disclosed the disappointing sales data. The SEC contends that these calls were made in an effort to lower Wall Street’s expectations such that AT&T would avoid missing the consensus estimate for the third consecutive quarter. According to the SEC, the disclosures were material and not shared with the general public. Notably, the case was not settled at the time of its filing, indicating AT&T’s intent to defend itself against the SEC’s charges.
Clear guidelines under Reg FD, and strict adherence to those rules, are essential to safeguard against the potential misuse of material nonpublic information. Most investment professionals, particularly private investment funds and broker-dealers, frequently communicate with senior management and investor relations personnel at public companies as part of their research process. Market participants generally rely on public company executives to know and follow Reg FD, and assume that statements made during these management meetings do not include MNPI. If broker-dealers or investment advisers receive MNPI from company management, they may violate insider trading laws by purchasing or selling securities or sharing the information with another party that buys or sells securities. This is true even though the public company executives themselves might have breached their own independent obligations under Reg FD.
The SEC’s case against AT&T and its investor relations personnel serves as an important reminder that investment professionals cannot simply assume corporate executives understand and comply with Reg FD, and that private fund managers and broker-dealers need to have policies and procedures in place that take into consideration the specific risks presented by meetings with corporate executives.
For example, it is important to carefully monitor communications with corporate executives and to independently confirm that all of the information conveyed in calls and meetings is either not material or is otherwise publicly available. Effective policies and procedures also should require that contemporaneous notes be prepared of meetings with management and that compliance take an active role in monitoring and taking notes at such meetings.
Of course, investment professionals also should be trained to recognize MNPI and understand it is their responsibility to ensure that they have not received MNPI. Other protective measures, such as reviews of meeting materials, should be employed as appropriate.
Authored by Charles J. Clark and Craig S. Warkol
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] The SEC also charged three AT&T investor relations employees with aiding and abetting AT&T’s violations.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2021 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

ARTICLE / CLIENT ALERT
March 9, 2021
Read time: 10 min
Guidance, both at the federal and state levels, has provided insight with respect to mandatory vaccination programs and has significantly expanded employees’ protections with respect to COVID-19. The U.S. Equal Employment Opportunity Commission (“EEOC”) published guidance on COVID-19 vaccines in December 2020, which is still currently in effect. The Occupational Safety and Health Administration (“OSHA”), acting pursuant to President Biden’s directive, posted COVID-19 guidance for employers entitled “Protecting Workers: Guidance on Mitigating and Preventing the Spread of COVID-19 in the Workplace.” The Centers for Disease Control and Prevention (“CDC”) also released guidance on workplace testing and guidance on recommendations for vaccinated individuals. The New York State Department of Labor (“NYS DOL”) issued guidance that broadens paid leave for employees who must quarantine or isolate as a result of COVID-19 (“NY COVID-19 Sick Leave”).
Employers are considering whether COVID-19 vaccinations may be made a mandatory condition of employment. The EEOC issued guidance on Dec. 16, 2020 which sheds light on this topic and sets forth important considerations for employers.
The EEOC guidance clarifies that vaccines are not “medical examinations” for the purposes of the Americans with Disabilities Act (“ADA”), 42 U.S.C. § 12112(d)(1). Notably, however, the guidance provides that pre-screening questions for a COVID-19 vaccination, as recommended by the CDC to ensure there is no medical reason that would prevent an employee from receiving the vaccination, are medical examinations since they are likely to elicit information about a disability. Under the ADA, employers may not administer medical examinations, and thus may not ask such pre-screening questions, unless the inquiries are “job-related and consistent with business necessity.” 42 U.S.C. § 12112(d)(4)(A).
The guidance, however, describes two ways in which disability-related screening may be accomplished without the need to satisfy such a standard: (1) make the vaccine program voluntary — therefore, answering pre-screening questions would be on a voluntary basis and would not implicate the ADA (42 U.S.C. § 12112(d)(4)(B)); or (2) have the employee receive the vaccination from a third party with which the employer is not contracting (e.g., pharmacy or health care provider) before returning to work. Simply requiring an employee to show proof of receipt of a COVID-19 vaccination, without more, would not be considered a medical examination according to the guidance. However, asking subsequent questions, such as why the employee did not receive the vaccination, would likely elicit information about a disability and therefore be considered a medical examination.
The EEOC guidance also discusses how to approach a situation where an employee indicates they are unable to receive the COVID-19 vaccination due to a disability. Before an employer may exclude such employee from the workplace, it must assess whether the employee poses a “direct threat” due to a “significant risk of substantial harm to the health or safety of the individual or others that cannot be eliminated or reduced by reasonable accommodation.” See also 42 U.S.C. § 12111(3). This analysis includes an individualized assessment regarding (1) the existence of the direct threat, (2) the duration of the risk, (3) the nature and severity of the potential harm, (4) the likelihood that the potential harm will occur and (5) the imminence of the potential harm. Note that even if such a direct threat exists, the employer may only exclude an employee if there is no way to provide a reasonable accommodation, absent undue hardship, “that would eliminate or reduce this risk so the unvaccinated employee does not pose a direct threat.” Moreover, the employer must determine if any other rights apply under any equal employment opportunity laws or other applicable federal, state or local authorities before terminating such employee. Similar to medical exemptions under the ADA, the employee may also be eligible to receive an accommodation for their sincerely held religious practice or belief, which is protected under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e-2(a)(1).
Since December 2020, various COVID-19 vaccinations have been granted emergency use authorization (“EUA”) by the U.S. Drug and Food Administration (“FDA”). This EUA mechanism facilitates the availability of countermeasures, like vaccines, during public health emergencies. Under the EUA, the FDA has not yet compiled and reviewed all evidence and clinical data it would otherwise examine before fully approving a drug for public use. However, the FDA has assured the public that the vaccine has met the necessary scientific standards to qualify for EUA and that “its known and potential benefits clearly outweigh its known and potential risks.”
As COVID-19 vaccines continue to become more widely available, employers are considering whether to require employees to be vaccinated in order to enter the workplace. On its face, subject to the considerations noted here, such a policy is lawful under federal law at present. However, mandating a vaccine that only has EUA creates heightened risks for employers. Notably, the Federal Food, Drug, and Cosmetics Act, which authorizes the FDA to grant EUA for vaccinations, also requires that the Secretary of Health and Human Services “ensure that individuals to whom the product is administered are informed … of the option to accept or refuse administration of the product.” 21 U.S.C. § 360bbb-3(e)(1)(A)(ii)(III). The EEOC guidance does not discuss this issue. It does, however, indicate that employers should remain vigilant and proceed with caution when either employers, themselves, are providing the vaccinations, or when employees request certain exemptions from the vaccination policy on the basis of a disability or sincerely held religious belief.
Simply because an employer may require its employees to be vaccinated for COVID-19, does not mean it should. Upon implementing such a policy, employers will need to address various concerns of employees who may refuse to be vaccinated, either for legally substantiated reasons (as noted above), or simply because they are uncomfortable. Moreover, other questions remain open about potential risks and liabilities employers potentially could face. Therefore, as an alternative to implementing a mandatory vaccination policy, employers should consider whether simply encouraging or strongly recommending employees be vaccinated is a viable and/or preferable option.
The CDC has also released guidance regarding individuals who have been fully vaccinated against COVID-19. This guidance is useful to employers who continue to strive for a safe workplace. Notably, the CDC guidance is clear that given the limited information about the vaccines and how long such protection may actually last, vaccinated individuals must continue to follow CDC guidance to protect themselves and others. This includes wearing a mask, maintaining social distance, avoiding crowds and practicing good hygiene. However, the guidance indicates that vaccinated persons who have been exposed to a suspected or confirmed case of COVID-19 are not required to quarantine if they meet the following conditions: (1) are fully vaccinated (i.e., it has been at least two weeks since they completed their vaccinations, including a second dose if taking a two-dose vaccine); (2) are within three months following the receipt of the last dose; and (3) have remained asymptomatic since the COVID-19 exposure. All three of these conditions must be met in order to bypass the quarantine requirement. Nevertheless, fully vaccinated individuals who do not quarantine should still monitor for COVID-19 symptoms for 14 days following exposure. The CDC is expected to issue further guidance on this.
The OSHA guidance encourages employers to create a COVID-19 prevention program in order to effectively reduce the spread of COVID-19 in the workplace. A COVID-19 prevention program should include:
In addition to the above, the OSHA guidance largely reiterates guidance from the CDC.
While the OSHA guidance does not confer any new legal requirements upon employers regarding workplace safety, in conducting investigations, OSHA usually considers an employer’s good-faith efforts to comply with health and safety standards and guidance. As a result, employers should consider the above as they design a workplace free from hazards.
The updated CDC guidance provides that workplace-based testing requires an employee’s informed consent. However, the guidance does not prohibit employers from mandating COVID-19 testing as a condition of entering the workplace.
According to the CDC guidance, employers that implement COVID-19 testing programs should:
As discussed in previous resources here and here, the NY COVID-19 Sick Leave law requires employers to provide paid and unpaid leave to New York employees who must quarantine or isolate due to a mandatory or precautionary order issued by any governmental body related to COVID-19.
The new NYS DOL guidance provides that employees can qualify for NY COVID-19 Sick Leave for up to three orders of quarantine or isolation. In no circumstances can an employee receive NY COVID-19 Sick Leave for more than three orders of quarantine or isolation. To qualify for the leave for the second and third quarantine or isolations orders, the employee must either (1) return to work following a period of quarantine or isolation and subsequently receive a positive COVID-19 diagnostic test result or (2) test positive for COVID-19 after the end of the initial quarantine or isolation period. Employees must submit documentation from a medical provider or testing facility confirming the positive test.
The new NYS DOL guidance further provides that an employee subject to a quarantine or isolation order does not need to be tested before returning to work and it is not recommended to have employees tested to discontinue isolation or quarantine. If such testing is nevertheless undertaken, employees who receive a positive test result are eligible for additional NY COVID-19 Sick Leave, as noted above.
The new NYS DOL guidance also seemingly creates an obligation to provide leave to employees who may not be subject to orders of quarantine or isolation in instances where an employer requires such employee to remain out of work due to exposure or potential exposure to COVID-19 (regardless of whether such exposure took place at work). In this instance, such employer would be required to continue to pay the employee, at the employee’s regular rate of pay, until (1) the employer allows the employee to return; or (2) the employee becomes subject to an order of quarantine or isolation, at which time the employee would be eligible for NY COVID-19 Sick Leave. Since the new NYS DOL guidance appears to create additional obligations for employers that go beyond the requirements of the statute, the guidance may be subject to legal challenge.
As always, if you have specific questions about any of the state or federal guidance or how it impacts your organization, you should contact your lawyer.
Authored by Mark E. Brossman, Scott A. Gold, Max Garfield, Donna K. Lazarus, and Michelle M. Orge.

ARTICLE / CLIENT ALERT
March 8, 2021
Read time: 4 min
Private companies with 100+ employees (and with at least one California-based employee) must report Equal Employment Opportunity (EEO) pay and other data to the California Department of Fair Employment and Housing (DFEH) by March 31, 2021, and annually thereafter. This requirement flows from California Senate Bill 973, enacted on September 30, 2020. The DFEH has provided additional information, sample forms and a place to submit the data here.
An extension on this deadline may be possible. The DFEH has recognized that some companies may not be in a position to report their first year’s data in a timely manner because of the pandemic or other extraordinary factors. Employers can request a deferral of enforcement on the March 31, 2021, submission deadline if they are unable to meet the March 31, 2021, deadline because of: (1) lost records because of flood, fire or other natural disaster; (2) severe economic hardship; or (3) reporting requires technology or infrastructure changes. To request an extension, the employer must directly submit a request for deferral prior to the March 31, 2021, deadline (an employer’s representative like a professional employer organization (PEO) cannot be the one to submit, and the employer must submit directly), using the online form located here.
Employers will need the following information to fill out the form:
Any extensions granted by the DFEH will provide the employer through April 30, 2021, to file its report with the DFEH.
For more information on the reporting requirement, including requesting an extension, the DFEH’s FAQs can be found here.
An extension on this deadline may be possible. The DFEH has recognized that some companies may not be in a position to report their first year’s data in a timely manner because of the pandemic or other extraordinary factors. Employers can request a deferral of enforcement on the March 31, 2021, submission deadline if they are unable to meet the March 31, 2021, deadline because of: (1) lost records because of flood, fire or other natural disaster; (2) severe economic hardship; or (3) reporting requires technology or infrastructure changes. To request an extension, the employer must directly submit a request for deferral prior to the March 31, 2021, deadline (an employer’s representative like a professional employer organization (PEO) cannot be the one to submit, and the employer must submit directly), using the online form located here.
Employers will need the following information to fill out the form:
Any extensions granted by the DFEH will provide the employer through April 30, 2021, to file its report with the DFEH.
For more information on the reporting requirement, including requesting an extension, the DFEH’s FAQs can be found here.

ARTICLE / CLIENT ALERT
March 8, 2021
Read time: 6 min
On March 5, 2021, the United Kingdom’s Financial Conduct Authority (“FCA”) announced (“Announcement”)[1] dates when all settings for the London Interbank Offered Rate (“LIBOR”) will cease to be provided by LIBOR’s administrator, the ICE Benchmark Administration (“IBA”), or will no longer be representative. As set forth in the Announcement, LIBOR rates either will no longer be published, or will cease to be representative, as follows:
The FCA reminded market participants that, although publications of certain LIBOR settings on a synthetic basis would be intended to assist legacy contract holders, new use of synthetic LIBOR by U.K.-regulated firms in regulated financial instruments would be prohibited under the BMR (as amended by a current bill in Parliament), and continued use by regulated firms in legacy financial instruments would also be subject to the FCA using its proposed powers to permit such use (which will be the subject of a consultations later in 2021).
In a follow-up to the Announcement by the FCA, the International Swaps and Derivatives Association Inc. (“ISDA”) announced[3] that the Announcement constitutes an “Index Cessation Event” under its IBOR Fallbacks Supplement and ISDA 2020 IBOR Fallbacks Protocol[4] for all 35 LIBOR settings. As a result of this, ISDA stated that the fallback spread adjustment published by Bloomberg has been fixed as of the date of the Announcement for all euro, sterling, Swiss franc, U.S. dollar and yen LIBOR settings. Bloomberg published a corresponding announcement[5] containing a table of fixed spread adjustments based on March 5, 2021 as the “Spread Adjustment Fixing Date” for all LIBOR tenors across all currencies. The fallbacks will automatically occur for outstanding derivatives contracts that incorporate the IBOR Fallbacks Supplement or are subject to adherence of the ISDA 2020 IBOR Fallbacks Protocol after Dec. 31, 2021 for outstanding derivatives referenced to all euro, sterling, Swiss franc and yen LIBOR settings, and after June 30, 2023 for outstanding derivatives referenced to all U.S. dollar LIBOR settings, where the rate for the 1-week and 2-month U.S. dollar LIBOR settings will be computed by each calculation agent using linear interpolation between the end of 2021 and June 30, 2023, before falling back to the adjusted risk-free rate plus spread.
The Alternative Reference Rates Committee (“ARRC”) also published a press release[6] commending the announcements regarding when LIBOR panels will end, including ISDA’s statement relating to an “Index Cessation Event.” The ARRC noted that when the panels for all U.S. dollar LIBOR tenors cease after June 2023 and the fallback rates apply, fallbacks for derivatives under the ISDA documentation will shift to the Secured Overnight Financing Rate (“SOFR”), which is the ARRC’s recommended fallback to U.S. dollar LIBOR, plus the spread adjustment that has now been fixed. The ARRC stated that its recommended spread adjustments for fallback language in non-consumer cash products will be the same as applicable to fallbacks in ISDA’s documentation for U.S. dollar LIBOR.
Authored by Phillip J. Azzollini, Taleah E. Jennings, Douglas I. Koff, Anna Maleva-Otto, Andi Mandell, Polly O’Brien, Daniel Oshinsky, Craig Stein and Atul Joshi.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
For the latest information on preparing for the transition from LIBOR, visit SRZ’s LIBOR Transition Resource Center.
[1] Read the FCA’s Announcement.
[2] The FCA notes that its proposed new powers under the BMR are subject to the Financial Services Bill being enacted by the U.K. Parliament. View the Financial Services Bill.
[3] View the ISDA announcement.
[4] View the IBOR Fallbacks Supplement and ISDA 2020 IBOR Fallbacks Protocol.
[5] View Bloomberg’s announcement on the spread fixing event.
[6] View the ARRC’s press release.
This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2021 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.
ARTICLE
March 5, 2021
Read time: 2 min
The challenges of the past year have underscored the importance of life sciences to a dramatic degree. With countries worldwide now distributing vaccines that were developed in record time, COVID-19 has also made plain the value of investing in technological and scientific solutions that can reshape the world and improve health outcomes.
The pandemic has particularly accelerated investments in the digital health space, as a significant share of everyday life has migrated to computer screens by necessity. So what does this mean for the sector going forward? Here are five themes to watch in the digital health sector, including what life sciences developers and investors should know about the current deal-making landscape.

ARTICLE
March 5, 2021
Read time: 1 min

ARTICLE / US POLICY
March 5, 2021
Read time: 1 min